Date: 12-Oct-2019

Zydus Cadila gets USFDA nod to market generic cholesterol lowering drug

Drug firm Zydus Cadila on Wednesday said it has received final approval from the US heath regulator to market generic cholesterol lowering Colesevelam Hydrochloride tablets. Zydus Cadila has received the final approval from the United States Food and Drug Administration (USFDA) to market Colesevelam Hydrochloride tablets, in the strength of 625 mg, the company said in a BSE filing. The product will be manufactured at the group's formulations manufacturing facility at SEZ, Ahmedabad, it added.